20 September 2018

On 14 september 2018, the Netherlands X-omics Initiative had their consortium kick-off meeting. Consortium members from the Dutch partners involved gathered to get to know each other and to determine the next steps to start up the project.

Introductions on the different aspects of the project provided insight in the state-of-the-art of current Dutch research facilities and technologies in the areas of genomics, proteomics, metabolomics and data integration & analysis. Subsequent break-out sessions led to fruitful discussions and the first plans of action to realize the Netherlands X-omics initiative.
 
The Netherlands X-omics Initiative received 17,3M euro funding from the NWO large scale scientific infrastructure program and is coordinated by Alain van Gool of the Radboudumc. The goals of the X-omics project are to push the technological boundaries of the individual omics technologies and to realize a genuinly integrated X-omics infrastructure. See www.x-omics.nl.
 

Related news items


TropIQ seeks new mosquito repellents

21 September 2021

TropIQ Health Sciences, a Radboudumc spin-off, has received a 1.3 million USD grant from the Bill & Melinda Gates Foundation to track down new mosquito repellents.

read more

New Automated PBMC isolation method introduced in LMI.

21 September 2021

The Radboud Biobank (RB) and the laboratory of Medical Immunology (LMI) are making plans to replace the density gradient centrifugation method with a new automated PBMC isolation method, the AutoMACS Pro Separator.

read more

Health-RI, geared up to accelerate

21 September 2021

The Dutch cabinet has selected Health-RI's National Growth Fund proposal for a national health data infrastructure. On 5 October, the kick-off will take place during a live meeting in Jaarbeurs Media Plaza in Utrecht.

read more

SUNRISE-CRC sub-biobank

21 September 2021

The main purpose of SUNRISE-CRC is to determine whether treatment with a high dose of sunitinib provides a better chance of survival and slows the progression of (colo)rectal cancer (CRC) more than standard treatment with TAS-102.

read more

PRECISE sub-biobank

21 September 2021

The aim of the PRECISE biobank is to develop the first, smart multi-modal liquid biopsy test service for the prediction of immune checkpoint inhibitor response in urothelial cancer (UC) patients – the PRECISE IVD.

read more

Lysine Metabolism sub-biobank

21 September 2021

Hereditary metabolic disorders form a large group of more than 1,400 rare disorders in which an error in the DNA causes abnormalities in the process in which proteins, fats and carbohydrates are converted into smaller building materials and energy.

read more